

# PET-CT REQUEST

PRIOR TO APPOINTMENT FAX OR EMAIL THIS FORM

Ph: 02 6126 5080 Fax: 02 8322 4025 Email: [petcanberra@qscan.com.au](mailto:petcanberra@qscan.com.au)



 Book online today [qscan.com.au/bookings](https://qscan.com.au/bookings)

## PATIENT DETAILS

Patient name

Medicare number

Birth date

Phone

Clinical trial / ID number

## EXAMINATION

PET with CT  PET only

## RADIOTRACER

FDG  FET  FEMPA  NaF  
 PSMA  Amyloid  FLT  Other

## Clinical Indications

Contrast Allergy

Renal Impairment

Surgery / Biopsy

Radiation Therapy

Chemotherapy

## MBS Eligible Items

- |  |   |  |
|--|---|--|
| <input type="checkbox"/> 61523 SPN Diagnosis             | <input type="checkbox"/> 61571 Uterine Cervix Staging   | <input type="checkbox"/> 61610 Metastatic SCC Staging            |
| <input type="checkbox"/> 61529 NSCLC Staging             | <input type="checkbox"/> 61575 Uterine Cervix Restaging | <input type="checkbox"/> 61620 Lymphoma Staging                  |
| <input type="checkbox"/> 61538 Brain Restaging           | <input type="checkbox"/> 61598 Head & Neck Staging      | <input type="checkbox"/> 61622 Lymphoma First Line Surveillance  |
| <input type="checkbox"/> 61559 Epilepsy Diagnosis        | <input type="checkbox"/> 61604 Head & Neck Restaging    | <input type="checkbox"/> 61628 Lymphoma Restaging                |
| <input type="checkbox"/> 61541 Colorectal Restaging      | <input type="checkbox"/> 61553 Melanoma Restaging       | <input type="checkbox"/> 61632 Lymphoma Second Line Surveillance |
| <input type="checkbox"/> 61577 Oesophageal / GOJ Staging | <input type="checkbox"/> 61524 PET Breast Staging       | <input type="checkbox"/> 61640 Bone/Soft Tissue Sarcoma Staging  |
| <input type="checkbox"/> 61565 Ovarian Restaging         | <input type="checkbox"/> 61525 PET Breast Staging       | <input type="checkbox"/> 61646 Sarcoma Restaging                 |

## Referred By

Contact details

Provider number

Send copy to

Date of follow up appointment

Signature .....

Date .....

## Qscan Canberra

University of Canberra  
Corner Broula and Allawoona Street  
Bruce, ACT 2617

Lung		
<b>Solitary Pulmonary Nodule</b> Diagnosis	<b>61523</b>	Whole body FDG PET study, performed for evaluation of a solitary pulmonary nodule where the lesion is considered unsuitable for transthoracic fine needle aspiration biopsy, or for which an attempt at pathological characterisation has failed.
<b>NSCLC</b> Staging	<b>61529</b>	Whole body FDG PET study, performed for the staging of proven non-small cell lung cancer, where curative surgery or radiotherapy is planned.
Brain		
<b>Brain</b> Restaging	<b>61538</b>	FDG PET study of the brain for evaluation of suspected residual or recurrent malignant brain tumour based on anatomical imaging findings, after definitive therapy (or during ongoing chemotherapy) in patients who are considered suitable for further active therapy.
<b>Epilepsy</b> Diagnosis	<b>61559</b>	FDG PET study of the brain, performed for the evaluation of refractory epilepsy which is being evaluated for surgery.
Gastrointestinal		
<b>Colorectal</b> Restaging	<b>61541</b>	Whole body FDG PET study, following initial therapy, for the evaluation of suspected residual, metastatic or recurrent colorectal carcinoma in patients considered suitable for active therapy.
<b>Oesophageal/GOJ</b> Staging	<b>61577</b>	Whole body FDG PET study, performed for the staging of proven oesophageal or GOJ carcinoma, in patients considered suitable for active therapy.
Gynaecology		
<b>Ovarian</b> Restaging	<b>61565</b>	Whole body FDG PET study, following initial therapy, performed for the evaluation of suspected residual, metastatic or recurrent ovarian carcinoma in patients considered suitable for active therapy.
<b>Uterine Cervix</b> Staging	<b>61571</b>	Whole body FDG PET study, for the further primary staging of patients with histologically proven carcinoma of the uterine cervix, at FIGO stage IB2 or greater by conventional staging, prior to planned radical radiation therapy or combined modality therapy with curative intent.
<b>Uterine Cervix</b> Restaging	<b>61575</b>	Whole body FDG PET study, for the further staging of patients with confirmed local recurrence of carcinoma of the uterine cervix considered suitable for salvage pelvic chemoradiotherapy or pelvic exenteration with curative intent.
Head & Neck		
<b>Head &amp; Neck</b> Staging	<b>61598</b>	Whole body FDG PET study performed for the staging of biopsy-proven newly diagnosed or recurrent head & neck cancer.
<b>Head &amp; Neck</b> Restaging	<b>61604</b>	Whole body FDG PET study performed for the evaluation of patients with suspected residual head & neck cancer after definitive treatment, and who are suitable for active therapy.
Melanoma		
<b>Melanoma</b> Restaging	<b>61553</b>	Whole body FDG PET study, following initial therapy, performed for the evaluation of suspected metastatic or recurrent malignant melanoma in patients considered suitable for active therapy.
SCC		
<b>Metastatic SCC unknown primary</b> Staging	<b>61610</b>	Whole body FDG PET study performed for the evaluation of metastatic squamous cell carcinoma of unknown primary site involving cervical nodes.
Lymphoma		
<b>Lymphoma</b> Staging	<b>61620</b>	Whole body FDG PET study for the initial staging of newly diagnosed or previously untreated Hodgkin's or non-Hodgkin's lymphoma.
<b>Lymphoma</b> Surveillance	<b>61622</b>	Whole body FDG PET study to assess response to first line therapy either during treatment or within three months of completing definitive first line treatment for Hodgkin's or non-Hodgkin's lymphoma.
<b>Lymphoma</b> Restaging	<b>61628</b>	Whole body FDG PET study for restaging following confirmation of recurrence of Hodgkin's or non-Hodgkin's lymphoma.
<b>Lymphoma</b> Surveillance	<b>61632</b>	Whole body FDG PET study to assess response to second-line chemotherapy if haemopoietic stem cell transplantation is being considered, for Hodgkin's or non-Hodgkin's lymphoma.
Sarcoma		
<b>Bone or Soft Tissue Sarcoma</b> Staging	<b>61640</b>	Whole body FDG PET study for initial staging of patients with biopsy-proven bone or soft tissue sarcoma (excluding gastrointestinal stromal tumour) considered by conventional staging to be potentially curable.
<b>Sarcoma</b> Restaging	<b>61646</b>	Whole body FDG PET study for the evaluation of patients with suspected residual or recurrent sarcoma (excluding gastrointestinal stromal tumour) after the initial course of definitive therapy to determine suitability for subsequent therapy with curative intent.
Breast		
<b>PET Breast</b> Staging	<b>61524</b>	Whole body FDG PET study, performed for the staging of locally advanced (stage III) breast cancer, for a patient who is considered suitable for active therapy (R) (Anaes.).
<b>PET Breast</b> Staging	<b>61525</b>	Whole body FDG PET study, performed for the evaluation of suspected metastatic or suspected locally or regionally recurrent breast carcinoma, for a patient who is considered suitable for active therapy (R) (Anaes.).

## Qscan Canberra

University of Canberra, corner Broula and Allawoona Street  
Bruce ACT 2617

Ph: 02 6126 5080 Fax: 02 8322 4025

Email: [petcanberra@qscan.com.au](mailto:petcanberra@qscan.com.au)

Electronic referrals are also available at [qscan.com.au/myresults](http://qscan.com.au/myresults)

